Teriflunomide for treatment of multiple sclerosis;Teriflunomid zur Behandlung der Multiplen Sklerose

Nervenarzt

Volumn 84, Issue 6, 2013, Pages 724-731

  Warnke, C ^a,b   Meyer Zu Horste G ^a   Menge, T ^a   Stuve O ^c   Hartung, H P ^a   Wiendl, H ^d   Kieseier, B C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

First line therapeutics; Immunotherapy; Leflunomide; Multiple sclerosis; Oral therapy

Indexed keywords

LEFLUNOMIDE; LIVER ENZYME; TERIFLUNOMIDE;

ARTICLE; BLOOD CELL COUNT; DISEASE COURSE; HUMAN; IMMUNOCOMPETENT CELL; MULTIPLE SCLEROSIS; RELAPSE; RHEUMATOID ARTHRITIS;

CENTRAL NERVOUS SYSTEM AGENTS; CROTONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; MULTIPLE SCLEROSIS; TOLUIDINES; TREATMENT OUTCOME;

EID: 84879506535     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-013-3779-7     Document Type: Article

References (42)

1. Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870-1880
2. Cherwinski HM, Mccarley D, Schatzman R et al (1995) The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 272:460-468
3. Claussen MC, Korn T (2012) Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 142:49-56
4. Clifford DB, De Luca A, Simpson DM et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438-446
5. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415
6. Confavreux C, Li DK, Freedman MS et al (2012) Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 18:1278-1289
7. FDA-geprüfte Produktionformation zu Teriflunomid in den USA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202992s000lbl.p
8. Fox RI (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53:20-26
9. Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198-208
10. Freedman MS, Wolinsky JS, Wamil B et al (2012) Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology 78:1877-1885
11. Freedman MS, Wolinsky JS, Frangin G et al (2010) Oral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. Conference paper. American Academy of Neurology. Toronto. Kanada
12. Gold R, Wolinsky JS (2011) Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 124:75-84
13. Gold RH, Hartung H-P, Stangel M et al (2012) Therapieziele von Basis- und Eskalationstherapien zur Behandlung der schubförmig-remittierenden Multiplen Sklerose. Aktuel Neurol:342-350
14. Greene S, Watanabe K, Braatz-Trulson J et al (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50:861-867
15. Hartung HP, Montalban X, Sorensen PS et al (2011) Principles of a new treatment algorithm in multiple sclerosis. Expert Rev Neur 11:351-362
16. Kappos L, Comi G, Confavreux C et al (2012) The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a Phase III placebo-controlled study. Conference paper. European Committee for treatment and research in MS. Lyon. Frankreich
17. Kieseier BC, Benamor M, Benzerdjeb H et al (2012) Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. Conference paper. European Committee for treatment and research in MS. Lyon. Frankreich
18. Kieseier BC, Wiendl H, Hartung HP et al (2009) The future of multiple sclerosis therapy. Pharmacol Res 60:207-211
19. Kieseier BC, Wiendl H, Hemmer B et al (2007) Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 20:286-293
20. Li EK, Tam LS, Tomlinson B (2004) Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 26:447-459
21. Limsakun T et al (2010) Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. Conference Paper. Congress of the Americas Committee on Treatment and Research in Multiple Sclerosis. San Antonio, USA
22. Maddison P, Kiely P, Kirkham B et al (2005) Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology 44:280-286
23. Miller AE, O'connor P, Wolinsky JS et al (2012) Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler 18:1625-1632
24. O'Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293-1303
25. O'Connor P, Wolinsky JS, Confavreux C (2011) Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomization. Mult Scler 17(Suppl 10):414
26. O'Connor PW, Li D, Freedman MS et al (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66:894-900
27. Osiri M, Shea B, Robinson V et al (2003) Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 30:1182-1190
28. Osiri M, Shea B, Robinson V et al (2003) Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev CD002047
29. Palazzo E, Yahia SA (2012) Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine 79:351-355
30. Pressemitteilung. http://en.sanofi.com/Images/31662-20120108-RDPIPELINE- en.pdf.
31. Ruckemann K, Fairbanks LD, Carrey EA et al (1998) Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 273:21682-21691
32. Tallantyre E, Evangelou N, Constantinescu CS (2008) Spotlight on teriflunomide. Int MS J 15:62-68 (MS Forum)
33. Vermersch P (2012) A multicenter, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Conference Paper. Congress of the Americas Committee on Treatment and Research in Multiple Sclerosis. San Diego. USA
34. Warnke C, Adams O, Hartung HP et al (2011) Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology. Nervenarzt 82:1314-1319
35. Warnke C, Menge T, Hartung HP et al (2010) Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 67:923-930
36. Warnke C, Meyer Zu Horste G, Hartung HP et al (2009) Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 5:333-340
37. Warnke C, Stuve O, Hartung HP et al (2011) Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 7:519-527
38. Pressemitteilung. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm319277.htm.
39. Wiendl H, Toyka KV, Rieckmann P et al (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255:1449-1463
40. http://clinicaltrials.gov/show/NCT00622700
41. http://www.genzyme.com
42. http://www.ema.europa.eu